Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival

Seymur Gahramanov, Csanad Varallyay, Rose M arie Tyson, Cynthia Lacy, Rongwei (Rochelle) Fu, Joao P rola Netto, Morad Nasseri, Tricia White, Randall (Randy) Woltjer, Sakir Gultekin, Edward Neuwelt

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

AIMS: This retrospective study determined the survival of glioblastoma patients with or without pseudoprogression.

METHODS: A total of 68 patients were included. Overall survival was compared between patients showing pseudoprogression (in most cases diagnosed using perfusion MRI with ferumoxytol) and in patients without pseudoprogession. MGMT methylation status was also analyzed in the pseudoprogression cases.

RESULTS: Median survival in 24 (35.3%) patients with pseudoprogression was 34.7 months (95% CI: 20.3-54.1), and 13.4 months (95% CI: 11.1-19.5) in 44 (64.7%) patients without pseudoprogression (p <0.0001). The longest survival was a median of 54.1 months in patients with combination of pseudoprogression and (MGMT) promoter methylation.

CONCLUSION: Pseudoprogression is associated with better outcome, especially if concurring with MGMT promoter methylation. Patients never diagnosed with pseudoprogression had poor survival. This study emphasizes the importance of differentiating tumor progression and pseudoprogression using perfusion MRI.

Original languageEnglish (US)
Pages (from-to)389-400
Number of pages12
JournalCNS oncology
Volume3
Issue number6
DOIs
StatePublished - Nov 1 2014

Fingerprint

Glioblastoma
Perfusion
Survival
Methylation
Ferrosoferric Oxide
Retrospective Studies
Neoplasms

Keywords

  • ferumoxytol
  • glioblastoma
  • perfusion MRI
  • pseudoprogression
  • temozolomide

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival. / Gahramanov, Seymur; Varallyay, Csanad; Tyson, Rose M arie; Lacy, Cynthia; Fu, Rongwei (Rochelle); Netto, Joao P rola; Nasseri, Morad; White, Tricia; Woltjer, Randall (Randy); Gultekin, Sakir; Neuwelt, Edward.

In: CNS oncology, Vol. 3, No. 6, 01.11.2014, p. 389-400.

Research output: Contribution to journalArticle

Gahramanov, S, Varallyay, C, Tyson, RMA, Lacy, C, Fu, RR, Netto, JPR, Nasseri, M, White, T, Woltjer, RR, Gultekin, S & Neuwelt, E 2014, 'Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival', CNS oncology, vol. 3, no. 6, pp. 389-400. https://doi.org/10.2217/cns.14.42
Gahramanov, Seymur ; Varallyay, Csanad ; Tyson, Rose M arie ; Lacy, Cynthia ; Fu, Rongwei (Rochelle) ; Netto, Joao P rola ; Nasseri, Morad ; White, Tricia ; Woltjer, Randall (Randy) ; Gultekin, Sakir ; Neuwelt, Edward. / Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival. In: CNS oncology. 2014 ; Vol. 3, No. 6. pp. 389-400.
@article{194158e69acd4180b22e429290c894b4,
title = "Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival",
abstract = "AIMS: This retrospective study determined the survival of glioblastoma patients with or without pseudoprogression.METHODS: A total of 68 patients were included. Overall survival was compared between patients showing pseudoprogression (in most cases diagnosed using perfusion MRI with ferumoxytol) and in patients without pseudoprogession. MGMT methylation status was also analyzed in the pseudoprogression cases.RESULTS: Median survival in 24 (35.3{\%}) patients with pseudoprogression was 34.7 months (95{\%} CI: 20.3-54.1), and 13.4 months (95{\%} CI: 11.1-19.5) in 44 (64.7{\%}) patients without pseudoprogression (p <0.0001). The longest survival was a median of 54.1 months in patients with combination of pseudoprogression and (MGMT) promoter methylation.CONCLUSION: Pseudoprogression is associated with better outcome, especially if concurring with MGMT promoter methylation. Patients never diagnosed with pseudoprogression had poor survival. This study emphasizes the importance of differentiating tumor progression and pseudoprogression using perfusion MRI.",
keywords = "ferumoxytol, glioblastoma, perfusion MRI, pseudoprogression, temozolomide",
author = "Seymur Gahramanov and Csanad Varallyay and Tyson, {Rose M arie} and Cynthia Lacy and Fu, {Rongwei (Rochelle)} and Netto, {Joao P rola} and Morad Nasseri and Tricia White and Woltjer, {Randall (Randy)} and Sakir Gultekin and Edward Neuwelt",
year = "2014",
month = "11",
day = "1",
doi = "10.2217/cns.14.42",
language = "English (US)",
volume = "3",
pages = "389--400",
journal = "CNS oncology",
issn = "2045-0915",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival

AU - Gahramanov, Seymur

AU - Varallyay, Csanad

AU - Tyson, Rose M arie

AU - Lacy, Cynthia

AU - Fu, Rongwei (Rochelle)

AU - Netto, Joao P rola

AU - Nasseri, Morad

AU - White, Tricia

AU - Woltjer, Randall (Randy)

AU - Gultekin, Sakir

AU - Neuwelt, Edward

PY - 2014/11/1

Y1 - 2014/11/1

N2 - AIMS: This retrospective study determined the survival of glioblastoma patients with or without pseudoprogression.METHODS: A total of 68 patients were included. Overall survival was compared between patients showing pseudoprogression (in most cases diagnosed using perfusion MRI with ferumoxytol) and in patients without pseudoprogession. MGMT methylation status was also analyzed in the pseudoprogression cases.RESULTS: Median survival in 24 (35.3%) patients with pseudoprogression was 34.7 months (95% CI: 20.3-54.1), and 13.4 months (95% CI: 11.1-19.5) in 44 (64.7%) patients without pseudoprogression (p <0.0001). The longest survival was a median of 54.1 months in patients with combination of pseudoprogression and (MGMT) promoter methylation.CONCLUSION: Pseudoprogression is associated with better outcome, especially if concurring with MGMT promoter methylation. Patients never diagnosed with pseudoprogression had poor survival. This study emphasizes the importance of differentiating tumor progression and pseudoprogression using perfusion MRI.

AB - AIMS: This retrospective study determined the survival of glioblastoma patients with or without pseudoprogression.METHODS: A total of 68 patients were included. Overall survival was compared between patients showing pseudoprogression (in most cases diagnosed using perfusion MRI with ferumoxytol) and in patients without pseudoprogession. MGMT methylation status was also analyzed in the pseudoprogression cases.RESULTS: Median survival in 24 (35.3%) patients with pseudoprogression was 34.7 months (95% CI: 20.3-54.1), and 13.4 months (95% CI: 11.1-19.5) in 44 (64.7%) patients without pseudoprogression (p <0.0001). The longest survival was a median of 54.1 months in patients with combination of pseudoprogression and (MGMT) promoter methylation.CONCLUSION: Pseudoprogression is associated with better outcome, especially if concurring with MGMT promoter methylation. Patients never diagnosed with pseudoprogression had poor survival. This study emphasizes the importance of differentiating tumor progression and pseudoprogression using perfusion MRI.

KW - ferumoxytol

KW - glioblastoma

KW - perfusion MRI

KW - pseudoprogression

KW - temozolomide

UR - http://www.scopus.com/inward/record.url?scp=84928111594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928111594&partnerID=8YFLogxK

U2 - 10.2217/cns.14.42

DO - 10.2217/cns.14.42

M3 - Article

VL - 3

SP - 389

EP - 400

JO - CNS oncology

JF - CNS oncology

SN - 2045-0915

IS - 6

ER -